Adjunctive corticosteroid therapy is safe for bacterial corneal ulcers

Article

Using adjunctive corticosteroid therapy is safe on bacterial corneal ulcers and does not alter best spectacle-corrected visual acuity (BSCVA)Using adjunctive corticosteroid therapy is safe on bacterial corneal ulcers and does not alter best spectacle-corrected visual acuity (BSCVA).

Using adjunctive corticosteroid therapy is safe on bacterial corneal ulcers and does not alter best spectacle-corrected visual acuity (BSCVA), claims a study in the Archives of Ophthalmology.

Dr Muthiah Srinvasan and his team, Department of Corneal and External Diseases, Aravind Eye Care System, Madurai, India, conducted a randomized, placebo-controlled, double-masked multicentered clinical trial on 1769 patients with bacterial corneal ulcers. All patients were screened between September 1, 2006 and February 22, 2010.

The primary outcome was BSCVA at 3 months from patient enrolment and the secondary outcomes were infiltrate/scar size, re-epithelialization and corneal perforation.

In the subgroups of baseline BSCVA and ulcer location there were a significant number of corticosteroids observed. There was no significant difference in the 3-month BSCVA infiltrate scar/size, time to re-epithelialization and corneal perforation.

Patients with vision of counting fingers or worse at baseline presented with 0.17 logMAR better visual acuity with corticosteroids. Patients that were at baseline had 0.20 logMAR better visual acuity with corticosteroids.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.